<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02752880</url>
  </required_header>
  <id_info>
    <org_study_id>104-7934A3,105-7009C,106-0917C</org_study_id>
    <nct_id>NCT02752880</nct_id>
  </id_info>
  <brief_title>YH1 in Poorly Controlled Type 2 Diabetes</brief_title>
  <official_title>The Efficacy and Safety of Concentrated Herbal Extract Granules, YH1, as an Add-On Medication in Poorly Controlled Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <brief_summary>
    <textblock>
      Type 2 diabetes mellitus is a chronic metabolic disease that seriously affects patients
      worldwide, and it is always among the top 10 causes of death in Taiwan. To date, still many
      patients who take more than three kinds of oral hypoglycemic agents could not effectively
      control their glycohemoglobin levels in clinics. Hypoglycemia as well as weight gain are
      common side effect with insulin therapy, and many patients in Taiwan are not willing to
      receive insulin injection. It is common for diabetic patients treated with Chinese herbal
      medicine in China currently, and some therapeutic effects have been published in
      international journals. In this study, we will evaluate whether Chinese herbal medicine, YH1,
      enhances the glycemic control and is safe as add-on medication in poorly controlled type 2
      diabetes patients.

      A total of 46 poorly controlled type 2 diabetes patients with glycohemoglobin ≥ 7% from
      Endocrinology and Metabolism clinics or Internal Chinese Medicine clinics will be enrolled in
      this randomized double-blind placebo-controlled trial. Subjects will be randomly assigned to
      receive either YH1 (6 g) or the placebo three times per day for 12 consecutive weeks. All
      subjects in both groups will also continuously receive their oral hypoglycemic agents without
      any dose or medicine change. During this 12-week period, the glycohemoglobin, fasting plasma
      glucose, 2h postprandial glucose, waist circumference, body weight, and body mass index will
      be assessed. In addition, insulin resistance, β -cell function, lipid profile, liver and
      renal function will also be evaluated. Independent statisticians will perform the data
      analysis at the end of the trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The YH1 in one batch number was used, manufactured by Sun Ten Pharmaceutical Co., LTD., a
      renowned GMP manufacturer of concentrated herbal extract granules conforming to international
      standards. The YH1 was prepared in small granules, including concentrated herbal extract
      granules of Rhizoma Coptidis (50%) and SLBZS (50%). Both medicines have already been approved
      by the Ministry of Health and Welfare in Taiwan as ethical drugs. YH1 granules were packed in
      aluminum foil packages. The placebo was also prepared as granules by Sun Ten Pharmaceutical
      Co., LTD., and the packaging of the placebo was identical to that of YH1. The chemical
      composition of YH1 was analyzed and profiled by using a high performance liquid
      chromatography (HPLC) with photodiode array (PDA) detection. Fourteen components, allantoin,
      atractylenolide III, berberine, coptisine, ginsenoside Rb1, ginsenoside Re, ginsenoside Rg1,
      glycyrrhizin, liquiritin, pachymic acid, palmatine, platycodin D, magnoflorin and quercitrin,
      were simultaneously used in the qualitative analysis under the developed HPLC-PDA method. As
      for the quantitative detection, each gram of YH1 contained 20.05 mg berberine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage Change in HbA1c Level From Baseline to 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary efﬁcacy endpoint was the percentage change in HbA1c levels from baseline to 12 weeks. The HbA1c level was measured by HPLC in the Department of Laboratory Medicine at Chang Gung Memorial Hospital.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage Change in 2hPG From Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The secondary efﬁcacy endpoint was the percentage change in 2hPG level from baseline to 12 weeks by using enzymatic method in the Department of Laboratory Medicine at Chang Gung Memorial Hospital.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>YH1 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YH1 with one batch number was manufactured by Sun Ten Pharmaceutical Co., Ltd., a renowned manufacturer of concentrated herbal extract granules conforming to the standards of good manufacturing practices (GMP) in New Taipei City, Taiwan. YH1 contains Rhizoma Coptidis (50 %) and Shen-Ling-Bai-Zhu-San (SLBZS) (50 %). SLBZS consists of Radix Ginseng, Poria, Rhizoma Atractylodis macrocephalae, Semen Lablab album, Rhizoma Dioscoreae, Embryo Nelumbinis, Radix Platycodonis, Semen Coicis, Fructus Amomi, Fructus Jujubae, and Radix Glycyrrhizae at a 3:3:3:2.3:3:1.5:1.5:1.5:1.5:1.5:3 ratio. Subjects in the YH1 group orally ingested two packages of granules (3 g/package) three times daily with warm water after a meal for 12 consecutive weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo was also prepared as granules by Sun Ten Pharmaceutical Co., Ltd., and the packaging of the placebo was identical to that of YH1. Subjects in the placebo group orally ingested two packages of granules (3 g/package) three times daily with warm water after a meal for 12 consecutive weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH1 group</intervention_name>
    <description>Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.</description>
    <arm_group_label>YH1 group</arm_group_label>
    <other_name>Rhizoma Coptidis and Shen-Ling-Bai-Zhu-San</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo group</intervention_name>
    <description>Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 20-75 years of age;

          2. Diagnosed as type 2 diabetics based on World Health Organization criteria [1];

          3. Body mass index (BMI) ≥ 23 kg/m2;

          4. Have been treated with ≥ 3 kinds of oral hypoglycemic agents (OHAs) with persistent (&gt;
             6 months) high HbA1c (≥ 7.0 %).

        Exclusion Criteria:

          1. Type 1 diabetes, gestational diabetes, or other specific types of diabetes;

          2. Have received insulin therapy in the past three months;

          3. Have serious gastrointestinal (GI) tract diseases, such as peptic ulcers or GI tract
             bleeding;

          4. Experience stressful situations, including diabetic ketoacidosis, nonketotic
             hyperosmolar diabetic coma, severe infection, or surgery in the previous one month;

          5. Suffer from hepatic insufficiency with alanine aminotransferase (ALT) 2 times the
             upper limit of normal or renal insufficiency with estimated glomerular filtration rate
             (eGFR) &lt; 60;

          6. Uncontrolled hypertension (blood pressure ≥ 160/100 mmHg);

          7. Mental illness, abused or addicted to alcohol, psychoactive substances or other drugs;

          8. Pregnant, lactating, or plan to become pregnant;

          9. Hemoglobin disease or chronic anemia;

         10. Have underlying conditions that could lead to poor compliance;

         11. History of cerebrovascular disease or myocardial infarction;

         12. Have undergone Chinese medicine treatment in the past two weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yueh-Hsiang Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital, Taoyuan, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>April 26, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2016</study_first_posted>
  <results_first_submitted>May 11, 2018</results_first_submitted>
  <results_first_submitted_qc>May 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 22, 2019</results_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT02752880/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>YH1 Three Times Per Day for 12 Consecutive Weeks</title>
          <description>The YH1 in one batch number was used, manufactured by a renowned GMP manufacturer of concentrated herbal extracts conforming to international standards.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo three times per day for 12 consecutive weeks.
placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>YH1 Group</title>
          <description>YH1 three times per day for 12 consecutive weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>placebo three times per day for 12 consecutive weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="33" upper_limit="69"/>
                    <measurement group_id="B2" value="56" lower_limit="40" upper_limit="66"/>
                    <measurement group_id="B3" value="52" lower_limit="33" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.1" lower_limit="7.5" upper_limit="11.3"/>
                    <measurement group_id="B2" value="8.7" lower_limit="7.6" upper_limit="11.8"/>
                    <measurement group_id="B3" value="8.6" lower_limit="7.5" upper_limit="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage Change in HbA1c Level From Baseline to 12 Weeks</title>
        <description>The primary efﬁcacy endpoint was the percentage change in HbA1c levels from baseline to 12 weeks. The HbA1c level was measured by HPLC in the Department of Laboratory Medicine at Chang Gung Memorial Hospital.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>YH1 Group</title>
            <description>YH1 three times per day for 12 consecutive weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>placebo three times per day for 12 consecutive weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage Change in HbA1c Level From Baseline to 12 Weeks</title>
          <description>The primary efﬁcacy endpoint was the percentage change in HbA1c levels from baseline to 12 weeks. The HbA1c level was measured by HPLC in the Department of Laboratory Medicine at Chang Gung Memorial Hospital.</description>
          <units>percentage change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.1" lower_limit="-30.2" upper_limit="14.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-20.4" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage Change in 2hPG From Baseline to Week 12</title>
        <description>The secondary efﬁcacy endpoint was the percentage change in 2hPG level from baseline to 12 weeks by using enzymatic method in the Department of Laboratory Medicine at Chang Gung Memorial Hospital.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>YH1 Group</title>
            <description>YH1 three times per day for 12 consecutive weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo three times per day for 12 consecutive weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage Change in 2hPG From Baseline to Week 12</title>
          <description>The secondary efﬁcacy endpoint was the percentage change in 2hPG level from baseline to 12 weeks by using enzymatic method in the Department of Laboratory Medicine at Chang Gung Memorial Hospital.</description>
          <units>percentage change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.2" lower_limit="-60.3" upper_limit="94.1"/>
                    <measurement group_id="O2" value="5.1" lower_limit="-43.0" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>YH1 Group</title>
          <description>During 12 weeks of YH1 treatment, participants were encouraged to report any discomfort to the project manager throughout the trial. Adverse events including any undesirable or unintended symptoms were assessed regardless of the causal relationship with the study drug.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>During 12 weeks of placebo treatment, participants were encouraged to report any discomfort to the project manager throughout the trial. Adverse events including any undesirable or unintended symptoms were assessed regardless of the causal relationship with the study drug.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal fullness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>acid reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. YH Huang</name_or_title>
      <organization>Chang Gung Memorial Hospital</organization>
      <phone>+886975360240</phone>
      <email>igighuang@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

